TGF-β1 leads to a reduction in the expression of the activating receptor natural killer group 2 (NKG2D) on the surface of both CD8+ T cells and NK cells, thereby hindering their cytotoxic effects on GBM cells [118]. This evidence concerns the gene CD8A and glioblastoma.